{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:42:45Z","timestamp":1793781765186,"version":"4.6.1"},"reference-count":37,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior","doi-asserted-by":"publisher","award":["KCLEXPOINDV19"],"award-info":[{"award-number":["KCLEXPOINDV19"]}],"id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,9,30]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injectable buprenorphine (BUP-XR) has been developed to enhance treatment effectiveness. This study aims to investigate the experiences of participants who have been offered BUP-XR (evaluation 1), health-related quality-of-life among participants who have opted to receive BUP-XR longer term (evaluation 2) and the experiences of participants allocated to receive BUP-XR or BUP-SL or MET with the offer of adjunctive personalised psychosocial intervention (evaluation 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Three qualitative\u2013quantitative (mixed-methods) evaluations embedded in a five-centre, head-to-head, randomised controlled trial of BUP-XR versus BUP-SL and MET in the UK. Evaluation 1 is a four-centre interview anchored on an OUD-related topic guide and conducted after the 24-week trial endpoint. Evaluation 2 is a two-centre interview anchored on medications for opioid use disorder-specific quality-of-life topic guide conducted among participants after 12\u201324 months. Evaluation 3: single-centre interview after the 24-week trial endpoint. All evaluations include selected trial clinical measures, with evaluation 2 incorporating additional questionnaires. Target participant recruitment for evaluations 1 and 2 is 15 participants per centre (n=60\u2009and n=30, respectively). Recruitment for evaluation 3 is 15 participants per treatment arm (n=30). Each evaluation will be underpinned by theory, drawing on constructs from the behavioural model for health service use or the health-related quality-of-life model. Qualitative data analysis will be by iterative categorisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Study protocol, consent materials and questionnaires were approved by the London-Brighton and Sussex research ethics committee (reference: 19\/LO\/0483) and the Health Research Authority (IRAS project number 255522). Participants will be provided with information sheets and informed written consent will be obtained for each evaluation. Study findings will be disseminated through peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>2018-004460-63.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067194","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:03:48Z","timestamp":1666346628000},"page":"e067194","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-5005","authenticated-orcid":false,"given":"Natalie","family":"Lowry","sequence":"first","affiliation":[{"name":"Addictions Department, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"South London and Maudsley Mental Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cowden","sequence":"additional","affiliation":[{"name":"Dundee Drug & Alcohol Recovery Service, Constitution House, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Day","sequence":"additional","affiliation":[{"name":"Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilish","family":"Gilvarry","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Treatment and Recovery (NTaR), Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Dundee Drug & Alcohol Recovery Service, Constitution House, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie","family":"Murray","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Treatment and Recovery (NTaR), Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Addictions Department, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"South London and Maudsley Mental Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mitcheson","sequence":"additional","affiliation":[{"name":"Addictions Department, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"South London and Maudsley Mental Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-2498","authenticated-orcid":false,"given":"John","family":"Marsden","sequence":"additional","affiliation":[{"name":"Addictions Department, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"South London and Maudsley Mental Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2025121508562834000_12.10.e067194.1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"key":"2025121508562834000_12.10.e067194.2","unstructured":"World Health Organization . Guidelines for the psychosocially assisted pharmacology treatment for opioid dependence. Geneva: WHO, 2009."},{"key":"2025121508562834000_12.10.e067194.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02284.x"},{"key":"2025121508562834000_12.10.e067194.4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/add.12971","article-title":"Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England","volume":"110","author":"White","year":"2015","journal-title":"Addiction"},{"key":"2025121508562834000_12.10.e067194.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025121508562834000_12.10.e067194.6","unstructured":"Public Health England . Alcohol and drug misuse and treatment statistics. Gov.uk, 2021."},{"key":"2025121508562834000_12.10.e067194.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108651","article-title":"Barriers to accessing opioid substitution treatment for opioid use disorder: a systematic review from the client perspective","volume":"221","author":"Hall","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121508562834000_12.10.e067194.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086"},{"key":"2025121508562834000_12.10.e067194.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.04.004"},{"key":"2025121508562834000_12.10.e067194.10","first-page":"5","article-title":"Treatment of patients with substance use disorders, second edition. American psychiatric association","volume":"164","author":"Kleber","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2025121508562834000_12.10.e067194.11","first-page":"335","article-title":"Increased effectiveness of drug abuse treatment from patient-program matching","volume":"43","author":"McLellan","year":"1983","journal-title":"NIDA Res Monogr"},{"key":"2025121508562834000_12.10.e067194.12","doi-asserted-by":"crossref","unstructured":"McKay JR . Treating substance use disorders with adaptive continuing care. 1st edn. Washington, DC: American Psychological Association, 2009: x, 277.","DOI":"10.1037\/11888-000"},{"key":"2025121508562834000_12.10.e067194.13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2215-0366(19)30097-5","article-title":"Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial","volume":"6","author":"Marsden","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2025121508562834000_12.10.e067194.14","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2025121508562834000_12.10.e067194.15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"Laffont","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2025121508562834000_12.10.e067194.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06595-0","article-title":"Extended-Release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone","volume":"23","author":"Marsden","year":"2022","journal-title":"Trials"},{"key":"2025121508562834000_12.10.e067194.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108667","article-title":"'Not at all what I had expected': discontinuing treatment with extended-release naltrexone (XR-NTX): a qualitative study","volume":"136","author":"Brenna","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025121508562834000_12.10.e067194.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-022-00474-2","article-title":"Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study","volume":"17","author":"Johnson","year":"2022","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025121508562834000_12.10.e067194.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: a qualitative study of patients' experiences in Australia","volume":"227","author":"Barnett","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025121508562834000_12.10.e067194.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108781","article-title":"Long-Acting depot buprenorphine in people who are homeless: views and experiences","volume":"139","author":"Matheson","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025121508562834000_12.10.e067194.21","unstructured":"Creswell J , Clark P . Designing and conducting mixed methods research. Thousand Oaks, CA: SAGE, 2007."},{"key":"2025121508562834000_12.10.e067194.22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/add.15259","article-title":"Iterative categorisation (IC) (Part 2): interpreting qualitative data","volume":"116","author":"Neale","year":"2021","journal-title":"Addiction"},{"key":"2025121508562834000_12.10.e067194.23","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/add.15405","article-title":"Acute impact of self-guided mental imagery on craving in cocaine use disorder: a mixed-methods analysis of a randomized controlled trial","volume":"116","author":"Lowry","year":"2021","journal-title":"Addiction"},{"key":"2025121508562834000_12.10.e067194.24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.03.018","article-title":"Development of the addiction dimensions for assessment and personalised treatment (adapt)","volume":"139","author":"Marsden","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"2025121508562834000_12.10.e067194.25","doi-asserted-by":"publisher","DOI":"10.2307\/2137284"},{"key":"2025121508562834000_12.10.e067194.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1547-5069.2005.00058.x"},{"key":"2025121508562834000_12.10.e067194.27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.12799\/jkachn.2016.27.4.358","article-title":"Factors influencing health-related quality of life of young adults and elderly with Multimorbiditiy: a secondary analysis of the 2013 Korea health panel data","volume":"27","author":"Joe","year":"2016","journal-title":"J Korean Acad Community Health Nurs"},{"key":"2025121508562834000_12.10.e067194.28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014172","article-title":"Health-Related quality of life in children, adolescents, and adults with a Fontan circulation: a meta-analysis","volume":"9","author":"Marshall","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025121508562834000_12.10.e067194.29","doi-asserted-by":"crossref","first-page":"e12174","DOI":"10.1111\/jspn.12174","article-title":"The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: analysis of narratives","volume":"22","author":"Draucker","year":"2017","journal-title":"J Spec Pediatr Nurs"},{"key":"2025121508562834000_12.10.e067194.30","unstructured":"First MB , Williams JBW , Karg RS , et al . Structured clinical interview for DSM-5-Research version (SCID-5, research version; SCID-5-RV). Arlington, VA: American psychiatric association, 2015."},{"key":"2025121508562834000_12.10.e067194.31","doi-asserted-by":"publisher","DOI":"10.1080\/08874417.2013.11645667"},{"key":"2025121508562834000_12.10.e067194.32","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2025121508562834000_12.10.e067194.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297"},{"key":"2025121508562834000_12.10.e067194.34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000484239","article-title":"Development of OSTQOL: a measure of quality of life for patients in opioid substitution treatment","volume":"23","author":"Strada","year":"2017","journal-title":"Eur Addict Res"},{"key":"2025121508562834000_12.10.e067194.35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10862-015-9529-3","article-title":"The difficulties in emotion regulation scale short form (DERS-SF): validation and replication in adolescent and adult samples","volume":"38","author":"Kaufman","year":"2016","journal-title":"J Psychopathol Behav Assess"},{"key":"2025121508562834000_12.10.e067194.36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.6.613"},{"key":"2025121508562834000_12.10.e067194.37","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-200203000-00008"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:56:34Z","timestamp":1765817794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2022-067194"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067194","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}